Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2019 Aug 01;962:148-157. doi: 10.1124/mol.119.116640.
Show Gene links
Show Anatomy links
The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
Musharrafieh R
,
Lagarias PI
,
Ma C
,
Tan GS
,
Kolocouris A
,
Wang J
.
???displayArticle.abstract???
The Food and Drug Administration-approved influenza A antiviral amantadine inhibits the wild-type (WT) AM2 channel but not the S31N mutant predominantly found in circulating strains. In this study, serial viral passages were applied to select resistance against a newly developed isoxazole-conjugated adamantane inhibitor that targets the AM2 S31N channel. This led to the identification of the novel drug-resistant mutation L46P located outside the drug-binding site, which suggests an allosteric resistance mechanism. Intriguingly, when the L46P mutant was introduced to AM2 WT, the channel remained sensitive toward amantadine inhibition. To elucidate the molecular mechanism, molecular dynamics simulations and binding free energy molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed on WT and mutant channels. It was found that the L46P mutation caused a conformational change in the N terminus of transmembrane residues 22-31 that ultimately broadened the drug-binding site of AM2 S31N inhibitor 4, which spans residues 26-34, but not of AM2 WT inhibitor amantadine, which spans residues 31-34. The MM-GBSA calculations showed stronger binding stability for 4 in complex with AM2 S31N compared with 4 in complex with AM2 S31N/L46P, and equal binding free energies of amantadine in complex with AM2 WT and AM2 L46P. Overall, these results demonstrate a unique allosteric resistance mechanism toward AM2 S31N channel blockers, and the L46P mutant represents the first experimentally confirmed drug-resistant AM2 mutant that is located outside of the pore where drug binds. SIGNIFICANCE STATEMENT: AM2 S31N is a high-profile antiviral drug target, as more than 95% of currently circulating influenza A viruses carry this mutation. Understanding the mechanism of drug resistance is critical in designing the next generation of AM2 S31N channel blockers. Using a previously developed AM2 S31N channel blocker as a chemical probe, this study was the first to identify a novel resistant mutant, L46P. The L46P mutant is located outside of the drug-binding site. Molecular dynamics simulations showed that L46P causes a dilation of drug-binding site between residues 22 and 31, which affects the binding of AM2 S31N channel blockers, but not the AM2 WT inhibitor amantadine.
Acharya,
Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus.
2010, Pubmed,
Xenbase
Acharya,
Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus.
2010,
Pubmed
,
Xenbase
Baker,
Electrostatics of nanosystems: application to microtubules and the ribosome.
2001,
Pubmed
Balannik,
Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel.
2010,
Pubmed
,
Xenbase
Balannik,
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.
2009,
Pubmed
,
Xenbase
Best,
Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.
2012,
Pubmed
Cady,
Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel.
2008,
Pubmed
Cady,
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers.
2010,
Pubmed
Chen,
The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding.
2008,
Pubmed
Gkeka,
Free Energy Calculations Reveal the Origin of Binding Preference for Aminoadamantane Blockers of Influenza A/M2TM Pore.
2013,
Pubmed
Homeyer,
Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method.
2012,
Pubmed
Homeyer,
Interpreting Thermodynamic Profiles of Aminoadamantane Compounds Inhibiting the M2 Proton Channel of Influenza A by Free Energy Calculations.
2016,
Pubmed
Hu,
Structure-Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers.
2018,
Pubmed
Hu,
Mechanisms of proton conduction and gating in influenza M2 proton channels from solid-state NMR.
2010,
Pubmed
Humphrey,
VMD: visual molecular dynamics.
1996,
Pubmed
Ioannidis,
Alchemical Free Energy Calculations and Isothermal Titration Calorimetry Measurements of Aminoadamantanes Bound to the Closed State of Influenza A/M2TM.
2016,
Pubmed
Jing,
Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel.
2008,
Pubmed
,
Xenbase
Jones,
Development and validation of a genetic algorithm for flexible docking.
1997,
Pubmed
Koynova,
Phases and phase transitions of the phosphatidylcholines.
1998,
Pubmed
Kwon,
The Influenza M2 Ectodomain Regulates the Conformational Equilibria of the Transmembrane Proton Channel: Insights from Solid-State Nuclear Magnetic Resonance.
2016,
Pubmed
Li,
Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction.
2017,
Pubmed
Lyman,
Ensemble-based convergence analysis of biomolecular trajectories.
2006,
Pubmed
Ma,
Asp44 stabilizes the Trp41 gate of the M2 proton channel of influenza A virus.
2013,
Pubmed
,
Xenbase
Ma,
Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
2016,
Pubmed
Ma,
Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel.
2009,
Pubmed
,
Xenbase
Ma,
Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.
2018,
Pubmed
,
Xenbase
McCown,
Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production.
2006,
Pubmed
Musharrafieh,
Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
2018,
Pubmed
Park,
The M2 ectodomain is important for its incorporation into influenza A virions.
1998,
Pubmed
Pettersen,
UCSF Chimera--a visualization system for exploratory research and analysis.
2004,
Pubmed
Pinto,
Influenza virus M2 protein has ion channel activity.
1992,
Pubmed
,
Xenbase
Rossman,
Influenza virus M2 protein mediates ESCRT-independent membrane scission.
2010,
Pubmed
Santner,
A Robust Proton Flux (pHlux) Assay for Studying the Function and Inhibition of the Influenza A M2 Proton Channel.
2018,
Pubmed
Santner,
Random Mutagenesis Analysis of the Influenza A M2 Proton Channel Reveals Novel Resistance Mutants.
2018,
Pubmed
Schmidt,
Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission.
2013,
Pubmed
Sharma,
Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer.
2010,
Pubmed
Stouffer,
Structural basis for the function and inhibition of an influenza virus proton channel.
2008,
Pubmed
Takeda,
Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture.
2002,
Pubmed
Tang,
The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue.
2002,
Pubmed
,
Xenbase
Thomaston,
Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters.
2018,
Pubmed
Verdonk,
Modeling water molecules in protein-ligand docking using GOLD.
2005,
Pubmed
Wang,
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
2013,
Pubmed
Wang,
In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.
2018,
Pubmed
Wang,
Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.
2013,
Pubmed
Wang,
Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.
2015,
Pubmed
Wu,
Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.
2014,
Pubmed
Zhou,
Modeling the membrane environment has implications for membrane protein structure and function: influenza A M2 protein.
2013,
Pubmed
